Literature DB >> 8043455

A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients.

T Facon1, M T Caulier, E Wattel, J P Jouet, F Bauters, P Fenaux.   

Abstract

Forty-two patients with ITP were randomly allocated to vinblastine slow infusion or bolus injection. 16/21 patients (76%) receiving slow infusion of vinblastine and 14/21 patients (67%) receiving a bolus injection of vinblastine had a response. There was no superiority of slow infusions of vinblastine over intravenous bolus injections, either when recently diagnosed and chronic ITP were analysed together or separately. In our opinion, intravenous bolus injections of vinblastine might be preferred, because they are easier to perform and have a better local tolerance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043455     DOI: 10.1111/j.1365-2141.1994.tb04810.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

3.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

Review 5.  Romiplostim as a treatment for immune thrombocytopenia: a review.

Authors:  Sarah Chalmers; Michael D Tarantino
Journal:  J Blood Med       Date:  2015-01-19

6.  Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.

Authors:  Lauren C Bylsma; Jon P Fryzek; Karynsa Cetin; Fiona Callaghan; Carla Bezold; Bhakti Mehta; Jeffrey S Wasser
Journal:  Am J Hematol       Date:  2018-10-21       Impact factor: 10.047

7.  Is dapsone still relevant in immune thrombocytopenia in resource limited settings?

Authors:  Preeti Dalal; Manisha Gulia; Monica Gupta; Anita Tahlan
Journal:  BMJ Case Rep       Date:  2019-12-19

8.  Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis.

Authors:  Yasuyuki Arai; Tomoyasu Jo; Hiroyuki Matsui; Tadakazu Kondo; Akifumi Takaori-Kondo
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941

Review 9.  Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice.

Authors:  Fei Song; Hanny Al-Samkari
Journal:  J Blood Med       Date:  2021-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.